Changeflow GovPing Pharma & Drug Safety Single-Domain Antibodies That Bind ROR1
Routine Notice Added Final

Single-Domain Antibodies That Bind ROR1

Favicon for changeflow.com USPTO Patent Grants - Peptides (C07K)
Published
Detected
Email

Summary

USPTO granted Patent US12600801B2 to Fred Hutchinson Cancer Center for single-domain antibodies binding receptor tyrosine kinase ROR1. The patent covers anti-cancer therapeutics, antibody-drug conjugates, multi-domain binding molecules, and cancer imaging/diagnostic agents. The patent contains 20 claims with inventors Jason Price, Colin E. Correnti, and James M. Olson.

What changed

USPTO granted Patent US12600801B2 to Fred Hutchinson Cancer Center covering single-domain antibodies that bind receptor tyrosine kinase ROR1. The antibodies have applications as anti-cancer therapeutics including antibody-drug conjugates, recombinant receptors, and cancer imaging/diagnostic agents.

For biotechnology and pharmaceutical companies, this patent establishes IP rights for ROR1-targeted cancer research and development. Parties interested in licensing this technology or developing competing therapies should monitor the patent portfolio and claim scope.

What to do next

  1. Monitor for updates

Archived snapshot

Apr 14, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Single-domain antibodies that bind ROR1

Grant US12600801B2 Kind: B2 Apr 14, 2026

Assignee

Fred Hutchinson Cancer Center

Inventors

Jason Price, Colin E. Correnti, James M. Olson

Abstract

Single-domain antibodies that bind receptor tyrosine kinase (ROR1) are described. The single-domain antibodies can be used for multiple purposes including in research, imaging, diagnosis, and treatment of ROR1-related conditions. The disclosed single-domain antibodies can be used as anti-cancer therapeutics such as antibody-drug conjugates, multi-domain binding molecules, or recombinant receptors or can be used as cancer imaging/diagnostic agents.

CPC Classifications

C07K 16/468 C07K 16/30 C07K 2317/31 C07K 2317/52 C07K 2317/565 C07K 2317/569 C07K 2317/77 C07K 16/2809 C07K 16/2803 C07K 2317/22 C07K 2317/24 C07K 2317/73

Filing Date

2023-07-11

Application No.

18350617

Claims

20

View original document →

Get daily alerts for USPTO Patent Grants - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 14th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12600801B2

Who this affects

Applies to
Pharmaceutical companies
Industry sector
3254.1 Biotechnology
Activity scope
Patent granting Biotechnology research Cancer therapeutics development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Regulatory Affairs
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!